What Polypeptide Therapeutic Solutions does

Polypeptide Therapeutic Solutions (PTS) is a private Spanish biotechnology manufacturer founded in 2012 and headquartered in Paterna, Spain. The company specializes in GMP-grade manufacturing of polyamino-acid (PAA) based nanoparticle encapsulation technology intended for advanced drug delivery applications. PTS operates as a specialty contract development and manufacturing organization (CDMO) within the pharmaceutical value chain, supplying formulation and encapsulation know-how to drug developers seeking delivery solutions for complex therapeutics such as nucleic acids, peptides, or other actives requiring nanoparticle carriers.

The company's underlying technical platform is centered on polyamino-acid based nanoparticles — a biocompatible polymer system used to encapsulate active pharmaceutical ingredients for controlled or targeted delivery. PTS describes its offering as GMP-grade, implying compliance with manufacturing standards required for clinical or commercial pharmaceutical supply. With a headcount of 11–50 employees, PTS functions as a small, science-driven manufacturing specialist rather than a large-scale commodity CDMO. Its leadership is anchored by CEO Robert Shaw and founders Maria Jesus VicentDocon and Benjumea Isabela Del Alcazar, suggesting a founder-led scientific organization with translational academic roots, likely connected to the biomedical research ecosystem in the Valencia region.

The company's revenue mechanics and go-to-market details are not disclosed in the available data. Pricing models, customer lists, distribution channels, and commercial partnerships are absent, indicating that PTS operates primarily as a B2B service provider to pharmaceutical and biotech clients under bespoke manufacturing or licensing arrangements. The thin public information footprint is consistent with a niche specialty manufacturer that relies on technical reputation and direct industry relationships rather than broad market visibility.

Name

Polypeptide Therapeutic Solutions

Website

https://pts-polypeptides.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Polypeptide Therapeutic Solutions is a Spain-based, GMP-grade manufacturer of polyamino-acid nanoparticle encapsulation technology serving pharmaceutical and biotech clients with advanced drug delivery needs.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery Manufacturing

NAICS

Plastics Material and Resin Manufacturing (325211), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)

SIC

Plastics Products, Nec (3089)

akta.pro primary industry

High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC)

akta.pro secondary industry

Medical & Pharmaceutical Thermoformed Packaging (IMANAHAB)

Keywords

• Drug delivery systems
• Nanoparticle encapsulation
• Polyamino-acid manufacturing
• GMP contract manufacturing
• Pharmaceutical nanocarriers

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure

Core offering

PTS is a GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications. The company produces polymeric nanocarrier systems intended for the encapsulation and delivery of therapeutic payloads for pharmaceutical and biotechnology customers. Manufacturing is performed to GMP quality standards in Paterna, Spain.

Differentiator

Problem solved

Functional benefit

Products and services

• Polyamino-acid (PAA) Nanoparticle Encapsulation Platform

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Direct peers

• Nanopharm (an Aptar Pharma company): Nanopharm specializes in nanoparticle and formulation development for inhaled and complex drug products. Its nanoparticle CDMO service offering overlaps with PTS's encapsulation technology for advanced therapeutics.
• Polymun Scientific: Polymun is an Austrian CDMO specializing in liposomal and nanoparticle drug delivery, including GMP manufacturing for clinical applications. It is a close functional peer of PTS as a GMP-grade nano-encapsulation service provider.
• Acuitas Therapeutics: Acuitas is a specialist developer of lipid nanoparticle (LNP) delivery systems used by mRNA vaccine and therapeutic developers. It is directly comparable to PTS as a focused, technology-led nano-delivery platform serving pharma and biotech partners.
• Ascendia Pharmaceuticals: Ascendia provides nanoemulsion and nanoparticle formulation CDMO services for poorly soluble drugs. It competes with PTS in the GMP formulation and encapsulation services market for pharma clients.

Emerging players

• Arcturus Therapeutics: Arcturus develops RNA medicines using its own lipid nanoparticle delivery platform. While primarily a therapeutic developer, its in-house LNP technology overlaps with PTS's nano-delivery focus.
• CD Bioparticles: CD Bioparticles manufactures and supplies polymer, lipid, and inorganic nanoparticles for drug delivery research. It overlaps with PTS in the nanoparticle fabrication space, though more on the reagent side.

Broad incumbents

• Evonik Health Care: Evonik's Health Care division offers specialty excipients, polymer-based delivery platforms (including polyamino-acid and PLGA systems), and CDMO services. It is a broader incumbent offering overlapping capabilities to PTS's customers.
• CureVac: CureVac is an mRNA therapeutics company with proprietary nanoparticle delivery technology. Its in-house delivery capabilities compete with specialist nano-delivery service providers like PTS for partner and pipeline opportunities.
• Croda International (Pharma): Croda's Pharma business supplies specialty excipients and delivery systems for advanced therapeutics, including lipid and polymer-based formulations, competing with PTS at the excipient and formulation service layer.
• NOF Corporation (Pharma Division): NOF supplies phospholipids, PEG derivatives, and polymer-based drug delivery materials to pharma and biotech. Its specialty excipients compete with PTS at the formulation-input layer for nano-encapsulation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/polypeptide-therapeutic-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polypeptide Therapeutic Solutions